Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Waxman/Hatch Policy Change Afforded Full White House Honors

Executive Summary

The White House Waxman/Hatch reform proposal reflects the policy development approach of FDA Chief Counsel Daniel Troy - and the Administration-insider status of incoming Commissioner Mark McClellan

Related Content

FDA Chief Counsel Troy Resigns; Agency Says It Will Still Support Preemption
Generic Drug Reform Outlook: Medicare Rx Bill May Be Best Vehicle
Bush Generic Drug Reform Proposal Unlikely To End Push For Legislation
Waxman/Hatch Reinterpretation Underpins Change In 30-Month Stay Policy
FDA Waxman/Hatch Fix Proposal Is “Beefed-Up” Patent Declarations
FDA Nominee McClellan Would Cement Agency’s Ties To Bush White House
FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation
Waxman/Hatch Reform Should Await Pending Supreme Court Decision – Hatch
FDA Waxman/Hatch “Moot Court” Will Examine Brand/Generic Legal Positions
FTC Asks FDA To Clarify "Orange Book" Listing Criteria In Citizen Petition



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts